Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1X3L0)

Drug Name
BGB-3245 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM1X3L0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Proto-oncogene c-RAF (c-RAF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Semapimod DMIJNLG Autoimmune diabetes 5A10 Phase 2 [2]
GDC-5573 DMJA27W Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Belvarafenib DM0ZNAR Solid tumour/cancer 2A00-2F9Z Phase 1 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-RAF (c-RAF) TTB18GJ RAF1_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of BeiGene.
2 Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.